The changing paradigm of chronic lymphocytic leukemia management

• Published in: European journal of internal medicine Vol. 24; no. 5; pp. 401 - 410
• Main Authors: Lobetti-Bodoni, Chiara, Bertoni, Francesco, Stussi, Georg, Cavalli, Franco, Zucca, Emanuele
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.07.2013
• Subjects: Antibodies, Monoclonal, Murine-Derived - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Chronic lymphocytic leukemia; Cyclophosphamide - therapeutic use; Humans; Internal Medicine; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - mortality; Prognosis; Rituximab; Therapy; Vidarabine - analogs & derivatives; Vidarabine - therapeutic use; Rituximab; Therapy; Chronic lymphocytic leukemia; Prognosis
• ISSN: 0953-6205; 1879-0828
• DOI: 10.1016/j.ejim.2013.03.009

Abstract B cell-chronic lymphocytic leukemia (CLL), the commonest adult leukemia in western world, is today most often diagnosed at early-stage, following the accidental detection of lymphocytosis during a routine blood analysis. Moreover, the expectations of CLL patients have dramatically changed in the past decade and for the first time a significant overall survival improvement has been demonstrated in the disease – at least in the younger and fit patients – with the use of the FCR regimen, which combines rituximab fludarabine and cyclophosphamide. New drugs and new regimens are currently being developed for the relapsed patients and for those too old or too frail to receive aggressive treatments. Some of these promising compounds will likely be part of the future front-line treatments. Additionally, the increasing knowledge on the molecular features that predict the clinical outcome may soon result in a molecular classification of the disease. These acquisitions are producing a migration from palliative care to a curative and individually-tailored approach. In this review we tried to summarize the advances achieved in the past decade and help the specialists in internal medicine and the general practitioners to understand the completely changed scenario in which the disease should nowadays be managed.